{"analyses":[{"ciLowerLimit":"1.1931","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.0803","groupDescription":"Patient level predictor: History of anemia at enrollment","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0116","paramType":"Odds Ratio (OR)","paramValue":"2.2064","statisticalMethod":"Regression, Logistic","testedNonInferiority":false},{"ciLowerLimit":"1.2754","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.1656","groupDescription":"Liver/renal/cardiac comorbidity as patient level predictor","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0057","paramType":"Odds Ratio (OR)","paramValue":"2.3049","statisticalMethod":"Regression, Logistic","testedNonInferiority":false},{"ciLowerLimit":"8.2159","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"37.4243","groupDescription":"Poor performance (ECOG \\>=2) during study as patient level predictor","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"17.5350","statisticalMethod":"Regression, Logistic","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1272"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1272"}],"units":"Participants"}],"description":"Objective 10: To model patient- and center-level variables between patients who died vs. survived during the course of primary or secondary prophylaxis with EP2006, in all patients and those with break-through FN episodes.\n\nTable presents patient-level predictors for all-cause mortality: history of anemia at enrollment, liver/renal/cardiac comorbidity, poor performance (ECOG \\>=2) during study","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN","id":"OG000","title":"EP2006"}],"paramType":"NUMBER","populationDescription":"Evaluable sample with data","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"Patient-level Predictors for All-cause Mortality","type":"SECONDARY","unitOfMeasure":"participants"}